Clinical trials: Proton Pump Inhibitor
Obstructive Sleep Apnea, Gastroesophageal Reflux
Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA) is common in modern society, affecting up to 5% of working middle-aged adults in the United States. Obesity is the number one risk factor for the development of OSA.
- Trial name
- NCT00211614
- Testing
- Lansoprazole
- Where
- United States
- Sponsor
- MetroHealth Medical Center
Gastrointestinal Symptoms, Small Intestinal Overgrowth
Proton Pump Inhibitors and Gastrointestinal Symptoms
The aim of the study is to evaluate the potential protective effect of Lactobacillus paracasei subspecies paracasei F19 administration on bowel symptom onset in patients with gastro-esophageal reflux disease at long-term PPI…
- Trial name
- NCT02054455
- Testing
- Lactobacillus paracasei F19
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Federico II University
Gastroesophageal Reflux Disease, Systemic Sclerosis
Gastroesophageal Reflux Treatment in Scleroderma
The investigators purposes are to define the prevalence of omeprazole resistance gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy of omeprazole in combination with algycon versus…
- Conditions
- Gastroesophageal Reflux Disease, Systemic Sclerosis, Scleroderma
- Trial name
- GERD-SSc (NCT01878526)
- Testing
- Alginic acid, Domperidone
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Khon Kaen University
Gastric Cancer, Bleeding
The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding
The aim of this study is the effect of proton pump inhibitor (PPI) with respect to gastric cancer bleeding in inoperable patients.
- Trial name
- NCT02150447
- Testing
- Proton pump inhibitor
- Where
- 4 sites in South Korea
- Volunteers
- 394 people
- Sponsor
- National Cancer Center, Korea
Non-erosive Gatroesophageal Reflux Disease
Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease
For ERD(erosive reflux disease), which pathogenesis is mainly the acid reflux mechanism, primary treatment is therefore PPI. However, NERD(non-erosive reflux disease) is much more complex than ERD and there are more factors…
- Trial name
- NCT03436914
- Testing
- PPI
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Yonsei University
Helicobacter Pylori
Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy
This study aims to compare the efficacy of the current standard first-line anti-helicobacter pylori regimen, extended proton pump inhibitor-based sequential therapy, with that of vonoprazan-based triple therapy, through a…
- Trial name
- NCT05371249
- Testing
- Vonoprazan-based triple therapy, Extended sequential therapy
- Where
- Taiwan
- Volunteers
- 628 people
- Sponsor
- Fu Jen Catholic University Hospital
Heartburn
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
Heartburn, a burning sensation in the chest or throat, occurs in many patients when acidic stomach contents move into the esophagus from the stomach.
- Trial name
- NCT00389948
- Testing
- Lanzoprazole
- Where
- 28 sites in United States
- Volunteers
- 576 people
- Sponsor
- Novartis
GERD
CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing
Background/Aim: To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P (CYP) 2C19 polymorphism in a population…
- Trial name
- NCT00354757
- Testing
- rabeprazole
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Gastroesophageal Reflux Disease
Lesogaberan in Chinese Patients With Refractory Reflux Symptoms
Lesogaberan may be used in Chinese GERD patients with partial response to PPI.
- Trial name
- NCT02818309
- Testing
- Lesogaberan
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- National Taiwan University Hospital
Gastroesophageal Reflux, Chronic Obstructive Pulmonary Disease
COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI
The purpose of this study is to determine which COPD patients have GERD and if COPD patients with GERD treated with high dose lansoprazole for 1 year decreases the frequency of COPD exacerbations compared to the previous year…
- Trial name
- GERD/COPD (NCT00523367)
- Testing
- 24 hour pH testing
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Florida
GERD Gastroesophageal Reflux Disease
The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
This study compares mechanical sphincter augmentation (LINX Reflux Management System) to double-dose proton pump inhibitors (PPIs) for the management of reflux symptoms related to gastroesophageal reflux disease (GERD).
- Trial name
- CALIBER (NCT02505945)
- Testing
- Omeprazole, LINX Reflux Management System
- Where
- 21 sites in United States
- Volunteers
- 152 people
- Sponsor
- Torax Medical Incorporated
Liver Cirrhosis, Hypertension, Portal
PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis. Half of participants will receive PPI, while the other half will receive a placebo.
- Trial name
- PPIs (NCT03175731)
- Testing
- Proton Pump Inhibitors
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Yanjing Gao
Nonfatal Myocardial Infarction, Coronary Death
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and…
- Trial name
- NCT01360073
- Where
- 2 sites in Spain, Sweden
- Volunteers
- 42,542 people
- Sponsor
- AstraZeneca
Pediatric Obesity, NAFLD
Effect of Obesity on Proton Pump Inhibitors
This longitudinal study tests the hypothesis that obesity affects drug pharmacology of acid suppression medications in children.
- Conditions
- Pediatric Obesity, NAFLD, GERD
- Trial name
- LiverLabPPI (NCT04248335)
- Testing
- Lansoprazole, Pantoprazole, Midazolam
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City